Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185931 | 0.92 | PLA2G1B (0.56) | PLA2G1BPLA2G2A | |
| SCHEMBL7192239 | 0.87 | PLA2G1B (0.64) | PLA2G1BPLA2G2A | |
| SCHEMBL7193741 | 0.84 | PLA2G1B (0.65) | PLA2G1BPLA2G2A | |
| SCHEMBL7618873 | 0.84 | PLA2G1B (0.55) | PLA2G1BPLA2G2A | |
| SCHEMBL13893783 | 0.83 | PLA2G1B (0.55) | PLA2G1BPLA2G2A | |
| SCHEMBL13632202 | 0.82 | PLA2G2F (0.53) | PLA2G1BPLA2G2A | |
| SCHEMBL13893693 | 0.80 | PLA2G1B (0.67) | PLA2G1BPLA2G2A | |
| SCHEMBL7186945 | 0.79 | PLA2G1B (0.67) | PLA2G1BPLA2G2A | |
| SCHEMBL7017169 | 0.78 | PLA2G1B (1.00) | PLA2G1B | |
| SCHEMBL13893708 | 0.78 | PLA2G1B (0.60) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6407104-B1 | Pyrrolo[1,2-a]pyrazine spla2 inhibitor | SHIONOGI & CO., LTD. (JP) | 2002-06-18 | — | — | US | claimed |
| CN-1303384-A | Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor | SHIONOGI & CO (JP) | 2001-07-11 | — | — | CN | claimed |
| EP-1066290-A1 | PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| WO-1999051605-A1 | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 1999-10-14 | — | — | WO | claimed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | disclosed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6407104-B1 | Pyrrolo[1,2-a]pyrazine spla2 inhibitor | SHIONOGI & CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-1066290-A1 | PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051605-A1 | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | PLA2G1B 26/4885PLA2G2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.